Chugai and Roche amend business arrangements on out-licensing
Japanese drugmaker Chugai POharmaceutical (TYO: 4591) has amended the business arrangements with its majority (62%) share-owner Swiss pharma major Roche (ROG: SIX) regarding the terms and conditions for out-licensing Chugai products based on the strategic alliance between the companies.
The announcement comes just a couple of weeks after speculation that Roche was seeking to acquire full control of Chugai for around $10 billion, although this was denied by the Japanese firm (The Pharma Letter August 18).
Under the basic alliance agreement concluded between Chugai and Roche in 2001, Chugai and Roche have agreed to the terms and conditions under which they may mutually license-in and license-out their products. Chugai and Roche have agreed to amend the business arrangements regarding the terms and conditions under which Roche may license-in Chugai products as follows:
Business arrangements originally agreed in 2001:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze